German biotech offers alternative to Cox-2 painkillers

08/16/2005 | DrugResearcher.com

Orthogen said it has developed autologous biotech proteins as a viable alternative to the Cox-2 painkillers as a treatment for arthritis and cartilage degeneration in joints. The Orthokine therapy involves injections of altered proteins obtained from the patient's own blood, which minimizes the prospect of allergic reactions, according to the firm.

View Full Article in:

DrugResearcher.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC